Nanomedicine regulating PSC-mediated intercellular crosstalk:Mechanisms and therapeutic strategies

扫码查看

原文链接

万方数据
维普

外文摘要：Pancreatic fibrosis(PF)is primarily distinguished by the stimulation of pancreatic stellate cells(PSCs)and excessive extracellular matrix deposition,which is the main barrier impeding drug de-livery and distribution.Recently,nanomedicine,with efficient,targeted,and controllable drug release characteristics,has demonstrated enormous advantages in the regression of pancreas fibrotic diseases.Notably,paracrine signals from parenchymal and immune cells such as pancreatic acinar cells,islet cells,pancreatic cancer cells,and immune cells can directly or indirectly modulate PSC differentiation and acti-vation.The intercellular crosstalk between PSCs and these cells has been a critical event involved in fi-brogenesis.However,the connections between PSCs and other pancreatic cells during the progression of diseases have yet to be discussed.Herein,we summarize intercellular crosstalk in the activation of PSCs and its contribution to the development of common pancreatic diseases,including pancreatitis,pancreatic cancer,and diabetes.Then,we also examine the latest treatment strategies of nanomedicine and potential targets for PSCs crosstalk in fibrosis,thereby offering innovative insights for the design of antifibrotic nanomedicine.Ultimately,the enhanced understanding of PF will facilitate the development of more pre-cise intervention strategies and foster individually tailored therapeutic approaches for pancreatic diseases.

外文关键词：

NanomedicinePancreatic fibrosisPancreatic stellate cellIntercellular crosstalkPancreatitisPancreatic cancerDiabetesTherapeutic strategies

作者：

Hui Wang、Liang Qi、Han Han、Xuena Li、Mengmeng Han、Lei Xing、Ling Li、Hulin Jiang

展开 >

作者单位：

Department of Endocrinology,Zhongda Hospital,School of Medicine,Southeast University,Nanjing 210009,China

State Key Laboratory of Natural Medicines,Department of Pharmaceutics,China Pharmaceutical University,Nanjing 210009,China

College of Pharmacy,Yanbian University,Yanji 133000,China

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals,China Pharmaceutical University,Nanjing 210009,China

Institute of Glucose and Lipid Metabolism,Southeast University,Nanjing 210009,China

Department of Clinical Science and Research,Zhongda Hospital,School of Medicine,Southeast University,Nanjing 210009,China

展开 >

出版年：

2024

DOI：

10.1016/j.apsb.2024.07.007

药学学报(英文版)

CSTPCD

ISSN：

年,卷(期)：2024.14(11)